TME Therapeutics Inc. (TME) and Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) have reached an agreement for TME to license its oligonucleotide product candidate to SKK.
Results of IIT for unresectable pancreatic cancer was published in GIE.
Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc. 87:1126-1131, 2018.
Phase 1/2a IIT program for unresectable pancreatic cancer was adopted by AMED innovative research program.